The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
A Randomized Trial of Aspirin to Prevent Colorectal Adenomas in Patients with Previous Colorectal Cancer
Abstract
BACKGROUND: Experimental studies in animals and observational studies in humans suggest that regular aspirin use may decrease the risk of colorectal adenomas, the precursors to most colorectal cancers. METHODS: We conducted a randomized, double-blind trial to determine the effect of aspirin on the incidence of colorectal adenomas. We randomly assigned 635 patients with previous colorectal cancer to receive either 325 mg of aspirin per day or placebo. We determined the proportion of patients with adenomas, the number of recurrent adenomas, and the time to the development of adenoma between randomization and subsequent colonoscopic examinations. Relative risks were adjusted for age, sex, cancer stage, the number of colonoscopic examinations, and the time to a first colonoscopy. The study was terminated early by an independent data and safety monitoring board when statistically significant results were reported during a planned interim analysis. RESULTS: A total of 517 randomized patients had at least one colonoscopic examination a median of 12.8 months after randomization. One or more adenomas were found in 17 percent of patients in the aspirin group and 27 percent of patients in the placebo group (P=0.004). The mean (+/-SD) number of adenomas was lower in the aspirin group than the placebo group (0.30+/-0.87 vs. 0.49+/-0.99, P=0.003 by the Wilcoxon test). The adjusted relative risk of any recurrent adenoma in the aspirin group, as compared with the placebo group, was 0.65 (95 percent confidence interval, 0.46 to 0.91). The time to the detection of a first adenoma was longer in the aspirin group than in the placebo group (hazard ratio for the detection of a new polyp, 0.64; 95 percent confidence interval, 0.43 to 0.94; P=0.022). CONCLUSIONS: Daily use of aspirin is associated with a significant reduction in the incidence of colorectal adenomas in patients with previous colorectal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2005) · Statistics for Biology and Health · doi:10.1007/0-387-27255-0_9 · Cited by 20,133
McCullagh, P., & Nelder, J. A. (1989) · doi:10.1007/978-1-4899-3242-6 · Cited by 16,836
Longitudinal Data Analysis for Discrete and Continuous Outcomes
Zeger, S. L., & Liang, K.-Y. (1986) · Biometrics · doi:10.2307/2531248 · Cited by 7,764
Generalized Linear Models (2nd ed.).
Therneau, T. M., McCullagh, P., & Nelder, J. A. (1993) · Journal of the American Statistical Association · doi:10.2307/2290358 · Cited by 4,907
The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis
Steinbach, G., Lynch, P. M., Phillips, R. K. S., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006293422603 · Cited by 2,526
Self-citationTreatment of Colonic and Rectal Adenomas with Sulindac in Familial Adenomatous Polyposis
Giardiello, F. M., Hamilton, S. R., Krush, A. J., Piantadosi, S., Hylind, L. M., Celano, P., Booker, S. V., Robinson, C. R., & Offerhaus, G. J. A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305063281805 · Cited by 1,717
Aspirin Use and Reduced Risk of Fatal Colon Cancer
Thun, M. J., Namboodiri, M. M., & Heath, C. W. (1991) · New England Journal of Medicine · doi:10.1056/nejm199112053252301 · Cited by 1,673
Colorectal cancer screening: Clinical guidelines and rationale
Winawer, S., Fletcher, R., Miller, L., Godlee, F., Stolar, M., Mulrow, C., Woolf, S., Glick, S., Ganiats, T., Bond, J., et al. (1997) · Gastroenterology · doi:10.1053/gast.1997.v112.agast970594 · Cited by 1,612
Thun, M. J., Henley, S. J., & Patrono, C. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.4.252 · Cited by 1,433
A Randomized Trial of Aspirin to Prevent Colorectal Adenomas
Baron, J. A., Cole, B. F., Sandler, R. S., Haile, R. W., Ahnen, D., Bresalier, R., McKeown-Eyssen, G., Summers, R. W., Rothstein, R., Burke, C. A., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021735 · Cited by 1,416
Self-citation
Cited by
Molecular Basis of Colorectal Cancer
Markowitz, S. D., & Bertagnolli, M. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804588 · Cited by 2,052
Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition
Simmons, D. L., Botting, R. M., & Hla, T. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.3.3 · Cited by 1,693
A Randomized Trial of Aspirin to Prevent Colorectal Adenomas
Baron, J. A., Cole, B. F., Sandler, R. S., Haile, R. W., Ahnen, D., Bresalier, R., McKeown-Eyssen, G., Summers, R. W., Rothstein, R., Burke, C. A., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021735 · Cited by 1,416
Self-citationRothwell, P. M., Wilson, M., Elwin, C.-E., Norrving, B., Algra, A., Warlow, C. P., & Meade, T. W. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61543-7 · Cited by 1,351
Low-Dose Aspirin for the Prevention of Atherothrombosis
Patrono, C., García Rodríguez, L. A., Landolfi, R., & Baigent, C. (2005) · New England Journal of Medicine · doi:10.1056/nejmra052717 · Cited by 1,218
Celecoxib for the Prevention of Sporadic Colorectal Adenomas
Bertagnolli, M. M., Eagle, C. J., Zauber, A. G., Redston, M., Solomon, S. D., Kim, K., Tang, J., Rosenstein, R. B., Wittes, J., Corle, D., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061355 · Cited by 1,048
Can we safely target the WNT pathway?
Kahn, M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4233 · Cited by 1,034
Celecoxib for the Prevention of Colorectal Adenomatous Polyps
Arber, N., Eagle, C. J., Spicak, J., Rácz, I., Dite, P., Hajer, J., Zavoral, M., Lechuga, M. J., Gerletti, P., Tang, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061652 · Cited by 975
Weir, H. K. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg040 · Cited by 867
Aspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival
Liao, X., Lochhead, P., Nishihara, R., Morikawa, T., Kuchiba, A., Yamauchi, M., Imamura, Y., Qian, Z. R., Baba, Y., Shima, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207756 · Cited by 843
Flossmann, E., & Rothwell, P. M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60747-8 · Cited by 820
Statins and the Risk of Colorectal Cancer
Poynter, J. N., Gruber, S. B., Higgins, P. D. R., Almog, R., Bonner, J. D., Rennert, H. S., Low, M., Greenson, J. K., & Rennert, G. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043792 · Cited by 816
The role of COX‐2 in intestinal inflammation and colorectal cancer
Wang, D., & DuBois, R. N. (2010) · Oncogene · doi:10.1038/onc.2009.421 · Cited by 805
Cook, N. R., Lee, I.-M., Gaziano, J. M., Gordon, D., Ridker, P. M., Manson, J. E., Hennekens, C. H., & Buring, J. E. (2005) · JAMA · doi:10.1001/jama.294.1.47 · Cited by 796
Aspirin and the Risk of Colorectal Cancer in Relation to the Expression of COX-2
Chan, A. T., Ogino, S., & Fuchs, C. S. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067208 · Cited by 781
Colorectal Cancer and Nutrition
Thanikachalam, K., & Khan, G. (2019) · Nutrients · doi:10.3390/nu11010164 · Cited by 729
Primary Prevention of Colorectal Cancer
Chan, A. T., & Giovannucci, E. L. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.057 · Cited by 723
Cuzick, J., Otto, F., Baron, J. A., Brown, P. H., Burn, J., Greenwald, P., Jankowski, J., La Vecchia, C., Meyskens, F., Senn, H. J., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70035-x · Cited by 714
Self-citationMetabolic targets for cancer therapy
Galluzzi, L., Kepp, O., Heiden, M. G. V., & Kroemer, G. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4145 · Cited by 711
Cancer associated fibroblasts (CAFs) in tumor microenvironment
Xing, F. (2010) · Frontiers in Bioscience · doi:10.2741/3613 · Cited by 682
Estrogen plus Progestin and Colorectal Cancer in Postmenopausal Women
Chlebowski, R. T., Wactawski-Wende, J., Ritenbaugh, C., Hubbell, F. A., Ascensao, J., Rodabough, R. J., Rosenberg, C. A., Taylor, V. M., Harris, R., Chen, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032071 · Cited by 669
Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways
Schetter, A. J., Heegaard, N. H. H., & Harris, C. C. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp272 · Cited by 657
Tumor microenvironment: The role of the tumor stroma in cancer
Li, H., Fan, X., & Houghton, J. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21159 · Cited by 646
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic
Warner, T. D., & Mitchell, J. A. (2004) · The FASEB Journal · doi:10.1096/fj.03-0645rev · Cited by 614
Aspirin Use and Survival After Diagnosis of Colorectal Cancer
Chan, A. T. (2009) · JAMA · doi:10.1001/jama.2009.1112 · Cited by 557
Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics
Ulrich, C. M., Bigler, J., & Potter, J. D. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1801 · Cited by 548
The Wnt signaling pathway in cancer
Duchartre, Y., Kim, Y.-M., & Kahn, M. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.12.005 · Cited by 548
C-Reactive Protein and the Risk of Incident Colorectal Cancer
Erlinger, T. P. (2004) · JAMA · doi:10.1001/jama.291.5.585 · Cited by 533
Ogino, S., Chan, A. T., Fuchs, C. S., & Giovannucci, E. (2011) · Gut · doi:10.1136/gut.2010.217182 · Cited by 522
Meyskens, F. L., McLaren, C. E., Pelot, D., Fujikawa-Brooks, S., Carpenter, P. M., Hawk, E., Kelloff, G., Lawson, M. J., Kidao, J., McCracken, J., et al. (2008) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0042 · Cited by 517
Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer
Carethers, J. M., & Jung, B. H. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.06.047 · Cited by 483
Targeting Wnt Signaling: Can We Safely Eradicate Cancer Stem Cells?
Takahashi-Yanaga, F., & Kahn, M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2943 · Cited by 499
Inflammatory networks underlying colorectal cancer
Lasry, A., Zinger, A., & Ben-Neriah, Y. (2016) · Nature Immunology · doi:10.1038/ni.3384 · Cited by 489
The role of aspirin in cancer prevention
Thun, M. J., Jacobs, E. J., & Patrono, C. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.199 · Cited by 481
Nitric oxide, a double edged sword in cancer biology: Searching for therapeutic opportunities
Mocellin, S., Bronte, V., & Nitti, D. (2007) · Medicinal Research Reviews · doi:10.1002/med.20092 · Cited by 478
Long-term Use of Aspirin and Nonsteroidal Anti-inflammatory Drugs and Risk of Colorectal Cancer
Chan, A. T. (2005) · JAMA · doi:10.1001/jama.294.8.914 · Cited by 478
Aspirin for the Chemoprevention of Colorectal Adenomas: Meta-analysis of the Randomized Trials
Cole, B. F., Logan, R. F., Halabi, S., Benamouzig, R., Sandler, R. S., Grainge, M. J., Chaussade, S., & Baron, J. A. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn485 · Cited by 476
Self-citationAspirin and colorectal cancer: the promise of precision chemoprevention
Drew, D. A., Cao, Y., & Chan, A. T. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.4 · Cited by 453
COX-2: A Molecular Target for Colorectal Cancer Prevention
Brown, J. R., & DuBois, R. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.051 · Cited by 444
A Randomized Trial of Rofecoxib for the Chemoprevention of Colorectal Adenomas
Baron, J. A., Sandler, R. S., Bresalier, R. S., Quan, H., Riddell, R., Lanas, A., Bolognese, J. A., Oxenius, B., Horgan, K., Loftus, S., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.08.079 · Cited by 433
Self-citationSenescence-associated inflammatory responses: aging and cancer perspectives
Lasry, A., & Ben-Neriah, Y. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.009 · Cited by 408
Molecular Link Mechanisms between Inflammation and Cancer
B. Vendramini-Costa, D., & E. Carvalho, J. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802083707 · Cited by 417
Ebrahim, S., & Davey Smith, G. (2008) · Human Genetics · doi:10.1007/s00439-007-0448-6 · Cited by 410
Chen, S. C., & Rex, D. K. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.01054.x · Cited by 403
Aspirin and Folic Acid for the Prevention of Recurrent Colorectal Adenomas
Logan, R. F. A., Grainge, M. J., Shepherd, V. C., Armitage, N. C., & Muir, K. R. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.10.014 · Cited by 398
Benamouzig, R., Deyra, J., Martin, A., Girard, B., Jullian, E., Piednoir, B., Couturier, D., Coste, T., Little, J., & Chaussade, S. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00887-4 · Cited by 395
Cyclooxygenases in cancer: progress and perspective
Zha, S., Yegnasubramanian, V., Nelson, W. G., Isaacs, W. B., & De Marzo, A. M. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.06.014 · Cited by 389
Meyerhardt, J. A., Mangu, P. B., Flynn, P. J., Korde, L., Loprinzi, C. L., Minsky, B. D., Petrelli, N. J., Ryan, K., Schrag, D. H., Wong, S. L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.7442 · Cited by 369
Self-citationJurasz, P., Alonso‐Escolano, D., & Radomski, M. W. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706013 · Cited by 357
Tsao, A. S., Kim, E. S., & Hong, W. K. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.3.150 · Cited by 331
Zhong, X., He, X., Wang, Y., Hu, Z., Huang, H., Zhao, S., Wei, P., & Li, D. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01358-5 · Cited by 329
Cancer and Inflammation: Promise for Biologic Therapy
Demaria, S., Pikarsky, E., Karin, M., Coussens, L. M., Chen, Y.-C., El-Omar, E. M., Trinchieri, G., Dubinett, S. M., Mao, J. T., Szabo, E., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181d32e74 · Cited by 325
A Large Cohort Study of Long-Term Daily Use of Adult-Strength Aspirin and Cancer Incidence
Jacobs, E. J., Thun, M. J., Bain, E. B., Rodriguez, C., Henley, S. J., & Calle, E. E. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk132 · Cited by 322
Platelets and cancer: a casual or causal relationship: revisited
Menter, D. G., Tucker, S. C., Kopetz, S., Sood, A. K., Crissman, J. D., & Honn, K. V. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9498-0 · Cited by 316
Takada, Y., Bhardwaj, A., Potdar, P., & Aggarwal, B. B. (2004) · Oncogene · doi:10.1038/sj.onc.1208169 · Cited by 310
Effect of Aspirin or Resistant Starch on Colorectal Neoplasia in the Lynch Syndrome
Burn, J., Bishop, D. T., Mecklin, J.-P., Macrae, F., Möslein, G., Olschwang, S., Bisgaard, M.-L., Ramesar, R., Eccles, D., Maher, E. R., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801297 · Cited by 300
Aspirin and cancer risk: a quantitative review to 2011
Bosetti, C., Rosato, V., Gallus, S., Cuzick, J., & La Vecchia, C. (2012) · Annals of Oncology · doi:10.1093/annonc/mds113 · Cited by 297
Drug repurposing in oncology—patient and health systems opportunities
Bertolini, F., Sukhatme, V. P., & Bouche, G. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.169 · Cited by 294
van Staa, T. P., Card, T., Logan, R. F., & Leufkens, H. G. M. (2005) · Gut · doi:10.1136/gut.2005.070896 · Cited by 287
Effect of aspirin and NSAIDs on risk and survival from colorectal cancer
Din, F. V. N., Theodoratou, E., Farrington, S. M., Tenesa, A., Barnetson, R. A., Cetnarskyj, R., Stark, L., Porteous, M. E., Campbell, H., & Dunlop, M. G. (2010) · Gut · doi:10.1136/gut.2009.203000 · Cited by 284
Aspirin, salicylates, and cancer
Elwood, P. C., Gallagher, A. M., Duthie, G. G., Mur, L. A., & Morgan, G. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60243-9 · Cited by 282
Fedirko, V., Bradshaw, P. T., Figueiredo, J. C., Sandler, R. S., Barry, E. L., Ahnen, D. J., Milne, G. L., Bresalier, R. S., & Baron, J. A. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-15-0212 · Cited by 278
Self-citationHawk, E. T., & Levin, B. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.097 · Cited by 278
Aspirin in the Chemoprevention of Colorectal Neoplasia: An Overview
Chan, A. T., Arber, N., Burn, J., Chia, W. K., Elwood, P., Hull, M. A., Logan, R. F., Rothwell, P. M., Schrör, K., & Baron, J. A. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0391 · Cited by 276
Self-citationWNT signaling in glioblastoma and therapeutic opportunities
Lee, Y., Lee, J.-K., Ahn, S. H., Lee, J., & Nam, D.-H. (2016) · Laboratory Investigation · doi:10.1038/labinvest.2015.140 · Cited by 273
Terry, M. B. (2004) · JAMA · doi:10.1001/jama.291.20.2433 · Cited by 271
Inclusion of patients in clinical trial analysis: the intention‐to‐treat principle
Heritier, S. R., Gebski, V. J., & Keech, A. C. (2003) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2003.tb05627.x · Cited by 270
Pathophysiology, Clinical Presentation, and Management of Colon Cancer
Cappell, M. S. (2008) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2007.12.002 · Cited by 256
The Role of Inflammation in Colon Cancer
Janakiram, N. B., & Rao, C. V. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-0348-0837-8_2 · Cited by 151
Pathi, S., Jutooru, I., Chadalapaka, G., Nair, V., Lee, S.-O., & Safe, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048208 · Cited by 127
Role of epigenetics in transformation of inflammation into colorectal cancer
Yang, Z.-H., Dang, Y.-Q., & Ji, G. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i23.2863 · Cited by 81
Robbins, L. B., Pfeiffer, K. A., Vermeesch, A., Resnicow, K., You, Z., An, L., & Wesolek, S. M. (2013) · BMC Public Health · doi:10.1186/1471-2458-13-474 · Cited by 39
“compliance [80].”
Autophagy-mediated metabolic effects of aspirin
Castoldi, F., Humeau, J., Martins, I., Lachkar, S., Loew, D., Dingli, F., Durand, S., Enot, D., Bossut, N., Chery, A., et al. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-00365-0 · Cited by 27
Metadata
- Authors
- Sandler, R. S., Halabi, S., Baron, J. A., Budinger, S., Paskett, E., Keresztes, R., Petrelli, N., Pipas, J. M., Karp, D. D., Loprinzi, C. L., Steinbach, G., & Schilsky, R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-03-06
- Volume
- 348
- Issue
- 10
- Pages
- 883-890
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1975076018
- Cited by
- 1,136
- References
- 45
- FWCI
- 62.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.